...
首页> 外文期刊>Acta biomaterialia >Preparation and characterization of starch-poly-epsilon-caprolactone microparticles incorporating bioactive agents for drug delivery and tissue engineering applications.
【24h】

Preparation and characterization of starch-poly-epsilon-caprolactone microparticles incorporating bioactive agents for drug delivery and tissue engineering applications.

机译:掺有生物活性剂的淀粉-聚-ε-己内酯微粒的制备和表征,用于药物输送和组织工程应用。

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

One limitation associated with the delivery of bioactive agents concerns the short half-life of these molecules when administered intravenously, which results in their loss from the desired site. Incorporation of bioactive agents into depot vehicles provides a means to increase their persistence at the disease site. Major issues are involved in the development of a proper carrier system able to deliver the correct drug, at the desired dose, place and time. In this work, starch-poly-epsilon-caprolactone (SPCL) microparticles were developed for use in drug delivery and tissue engineering (TE) applications. SPCL microparticles were prepared by using an emulsion solvent extraction/evaporation technique, which was demonstrated to be a successful procedure to obtain particles with a spherical shape (particle size between 5 and 900 microm) and exhibiting different surface morphologies. Their chemical structure was confirmed by Fourier transform infrared spectroscopy. To evaluate the potential of the developed microparticles as a drug delivery system, dexamethasone (DEX) was used as model drug. DEX, a well-known component of osteogenic differentiation media, was entrapped into SPCL microparticles at different percentages up to 93%. The encapsulation efficiency was found to be dependent on the polymer concentration and drug-to-polymer ratio. The initial DEX release seems to be governed mainly by diffusion, and it is expected that the remaining DEX will be released when the polymeric matrix starts to degrade. In this work it was demonstrated that SPCL microparticles containing DEX can be successfully prepared and that these microparticular systems seem to be quite promising for controlled release applications, namely as carriers of important differentiation agents in TE.
机译:与生物活性剂的递送相关的一个限制涉及当静脉内施用时这些分子的短半衰期,这导致它们从所需位点损失。将生物活性剂掺入仓库车辆中提供了增加其在疾病部位的持久性的手段。主要问题涉及开发合适的载体系统,该系统能够以所需的剂量,位置和时间递送正确的药物。在这项工作中,开发了淀粉-聚ε-己内酯(SPCL)微粒,用于药物递送和组织工程(TE)应用。通过使用乳液溶剂萃取/蒸发技术制备SPCL微粒,事实证明这是获得球形(粒径在5到900微米之间)并表现出不同表面形态的颗粒的成功方法。通过傅立叶变换红外光谱法证实了它们的化学结构。为了评估已开发的微粒作为药物递送系统的潜力,地塞米松(DEX)被用作模型药物。 DEX是成骨分化培养基的一种众所周知的成分,以高达93%的不同百分比被包埋在SPCL微粒中。发现包封效率取决于聚合物浓度和药物与聚合物的比率。最初的DEX释放似乎主要由扩散决定,并且可以预期,当聚合物基质开始降解时,其余的DEX将会释放。在这项工作中,证明了可以成功制备含DEX的SPCL微粒,并且这些微粒系统对于控释应用(即作为TE中重要的分化剂的载体)似乎非常有前途。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号